Pacira outlines 2026 revenue guidance of $745M-$770M while advancing PCRX-201 Phase II milestones
Pacira BioSciences, Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $22.96
-6.5% in 7d after detection
Post-detection moves
1h
—
1d
+1.0%
3d
-3.1%
7d
-6.5%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS